Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial
Saravanan P, Bridgewater B, West AL, O'Neill SC, Calder PC, Davidson NC
Circulation. Arrhythmia and electrophysiology · 119 citas
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Eventos clínicos como enfermedad o muerte
Quién lo pagó
- Financiación
- Financiación independiente
- Organización sin fines de lucro
- British Heart Foundation
- Subvenciones
- British Heart Foundation (FS/06/033)
Según 1 financiador declarado.
Publicación
- Publicado
- 2009-12-31 · Circ Arrhythm Electrophysiol · vol. 3 · número 1 · págs. 46–53
- Editorial
- Lippincott Williams & Wilkins
- Citado
- 172 citas · más que el 100% de estudios similares · 23.5× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 49 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Atrial Fibrillation Management and Outcomes · Cardiac Health and Mental Health
- Palabras clave
- omega-3 polyunsaturated fatty acids, atrial fibrillation, coronary artery bypass grafting, postoperative arrhythmia, atrial fibrillation burden, AF-free survival, olive oil placebo
- MeSH
- heart atria, humans, atrial fibrillation, fatty acids, omega-3, c-reactive protein, echocardiography, electrocardiography, preoperative care, coronary artery bypass, double-blind method, aged, middle aged, female, male
6 autores
- Palaniappan Saravanan🇬🇧University of Manchester; University of Southampton
- Ben Bridgewater🇬🇧University of Manchester; University of Southampton
- Annette L. West🇬🇧University of Manchester; University of Southampton
- Stephen C. O'Neill🇬🇧University of Manchester; University of Southampton
- Philip C. Calder🇬🇧University of Manchester; University of Southampton
- Neil C. Davidson🇬🇧University of Manchester; University of Southampton
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Omega-3 polyunsaturated fatty acids (n-3 PUFA) have been reported to reduce the risk of sudden cardiac death presumed to be due to fatal ventricular arrhythmias, but their effect on atrial arrhythmias is unclear.
Methods and results
Patients (n=108) undergoing coronary artery bypass graft surgery were randomly assigned to receive 2 g/d n-3 PUFA or placebo (olive oil) for at least 5 days before surgery (median, 16 days; range, 12 to 21 days). Phospholipid n-3 PUFA were measured in serum at study entry and at surgery and in right atrial appendage tissue at surgery. Echocardiography was used to assess left ventricular function and left atrial dimensions. Postoperative continuous ECG monitoring (Lifecard CF) for 5 days or until discharge, if earlier, was performed with a daily 12-lead ECG and clinical review if patients remained in the hospital beyond 5 days. Lifecard recordings were analyzed for episodes of atrial fibrillation (AF) > or =30 seconds (primary outcome). Clinical AF, AF burden (% time in AF), hospital stay, and intensive care/high dependency care stay were measured as secondary outcomes. One hundred three patients completed the study (51 in the placebo group and 52 in the n-3 PUFA group). There were no clinically relevant differences in baseline characteristics between groups. n-3 PUFA levels were higher in serum and right atrial tissue in the active treatment group. There was no significant difference between groups in the primary outcome of AF (95% confidence interval [CI], -6% to 30%, P=0.28) in any of the secondary outcomes or in AF-free survival.
Conclusions
Omega-3 PUFA do not reduce the risk of AF after coronary artery bypass graft surgery. Clinical Trial Registration- www.ukcrn.org.uk. Identifier: 4437.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.